Table 1.
Exon/intron usage and biological relevance of apoptosis-related alternative splicing (AS) events.
| Gene | AS Region | AS Type | Splicing Regulator | Biological Signatures | Reference |
|---|---|---|---|---|---|
| Survivin | Exon 3 Exon 2B |
Exon skipping Exon skipping |
uncharacterized | anti-apoptosis (Survivin ∆Ex3 and 3β) pro-apoptosis (Survivin 2β and 2α) |
[49,50,51,52] |
|
ERa ERb |
Exon 7 Exon 10/11 |
Exon skipping Exon skipping |
hnRNP G, Tra2b unclear |
anti-apoptosis (ERα+7) pro-apoptosis (ERRb2) anti-apoptosis (ERRβsf) |
[60,61,62,63] |
| Transient receptor potential melastatin 8 | Exon 5a | Exon skipping | uncharacterized | anti-apoptosis (sTRPM8α) | [65,66,67] |
| Interleukin-15 | Exon 6 | Exon skipping | uncharacterized | pro-apoptosis (IL-15ΔE6) | [69,70] |
| p53 | Exon β/γ | Exon skipping | uncharacterized | pro-apoptosis (p53β variants) | [72,73,74,75,76] |
| Fas | Exon 6 | Exon skipping | TIA-1/TIAR, PTBP1, HuR, hnRNP C | anti-apoptosis (Fas−exon 6) pro-apoptosis (Fas) |
[79,80,81,82,83,84,85] |
| c-FLIP | Exon 5 | Alternative 5′ SS | RBM5/10 | pro-apoptosis (c-FLIPL) anti-apoptosis (c-FLIPS) |
[87,88] |
| Bcl-x | Exon 2 | Alternative 5′ SS | SRSF1, PTBP1, RBM4, RBM5, RBM10, and RBM11 | anti-apoptosis (Bcl-xL) pro-apoptosis (Bcl-xS) |
[91,92,93,94,95,96] |
| Bax | Exon 3 | Exon skipping | uncharacterized | pro-apoptosis (Bax and BaxΔ2) | [99,100] |
| BIM | Exon 3/4 | Mutual selection | SRSF1 | pro-apoptosis (BIM+exon 3) anti-apoptosis (BIM+exon 4) |
[101,102,103,104] |